Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027497 (nausea)
 23,468 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Alternative pharmacologic adjuncts are needed for the management of opiate abuse. Oxilorphan, a narcotic antagonist, was studied at 5 different dose levels (1, 2, 4, 6, and 8 mg) in 30 normal subjects to determine the relation of single oral doses and toxicity. The drug causes pupillary constriction and mild central nervous system side effects (nausea, dizziness) at all doses. Mean urine volume increased (P less than 0.05) during the 12 hours after 1 and 2 mg. Oxilorphan has partial agonist properties similar to dl-cyclazocine.
 ...
PMID:Partial agonist properties and toxicity of oral oxilorphan. 0 72

Oxilorphan (levo-BC-2605) is a new, long-acting, narcotic antagonist that has agonist properties. Twenty-one (21) heroin addicts in Los Angeles were detoxified and given at least one oral dose of oxilorphan. Only three (14.3%) patients took daily doses for 14 days, which was the maximal time allowed for oxilorphan administration in this study. The remainder discontinued oxilorphan because of subjective side effects or for unknown reasons. Side effects most responsible for dropouts were dysphoria, insomnia, weakness, hallucinations, nausea, drowsiness and anorexia. Oxilorphan provided 24-hour protection with a single, oral dose, but subjective side effects encountered during inductiolinical trials with oxilorphan should be attempted with other addict populations to fully determine its potential therapeutic value.
 ...
PMID:Clinical trial in post-addicts with oxilorphan (levo-BC-2605): a new narcotic antagonist. 1 84